HomeCompareLLY vs WIT

LLY vs WIT: Dividend Comparison 2026

LLY yields 0.70% · WIT yields 5.59%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 WIT wins by $11605.01M in total portfolio value
10 years
LLY
LLY
● Live price
0.70%
Share price
$886.67
Annual div
$6.23
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.54M
Annual income
$1,207,534.19
Full LLY calculator →
WIT
WIT
● Live price
5.59%
Share price
$2.07
Annual div
$0.12
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$11606.55M
Annual income
$11,220,668,219.46
Full WIT calculator →

Portfolio growth — LLY vs WIT

📍 WIT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLLYWIT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LLY + WIT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LLY pays
WIT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LLY
Annual income on $10K today (after 15% tax)
$59.72/yr
After 10yr DRIP, annual income (after tax)
$1,026,404.06/yr
WIT
Annual income on $10K today (after 15% tax)
$474.81/yr
After 10yr DRIP, annual income (after tax)
$9,537,567,986.54/yr
At 15% tax rate, WIT beats the other by $9,536,541,582.48/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LLY + WIT for your $10,000?

LLY: 50%WIT: 50%
100% WIT50/50100% LLY
Portfolio after 10yr
$5804.04M
Annual income
$5,610,937,876.83/yr
Blended yield
96.67%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on LLY right now

LLY
Analyst Ratings
33
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$1,243.95
+40.3% upside vs current
Range: $985.00 — $1,350.00
Altman Z
7.7
Piotroski
6/9
WIT
Analyst Ratings
4
Buy
10
Hold
7
Sell
Consensus: Hold
Price Target
$7.35
+255.1% upside vs current
Range: $7.00 — $7.70
Altman Z
4.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LLY buys
0
WIT buys
0
No recent congressional trades found for LLY or WIT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLLYWIT
Forward yield0.70%5.59%
Annual dividend / share$6.23$0.12
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%100%
Portfolio after 10y$1.54M$11606.55M
Annual income after 10y$1,207,534.19$11,220,668,219.46
Total dividends collected$1.49M$11579.69M
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyHold
Analyst price target$1,243.95$7.35

Year-by-year: LLY vs WIT ($10,000, DRIP)

YearLLY PortfolioLLY Income/yrWIT PortfolioWIT Income/yrGap
1← crossover$10,841$140.53$11,817$1,117.20$976.00WIT
2$11,884$284.74$15,112$2,467.69$3.2KWIT
3$13,299$583.47$22,069$5,898.58$8.8KWIT
4$15,451$1,220.47$39,714$16,100.60$24.3KWIT
5$19,183$2,650.30$96,651$54,157.39$77.5KWIT
6$26,676$6,150.32$349,776$246,359.23$323.1KWIT
7$44,530$15,986.45$2,040,731$1,666,470.39$2.00MWIT
8$97,527$49,880.25$20,357,117$18,173,535.39$20.26MWIT
9$308,551$204,197.51$360,638,911$338,856,795.79$360.33MWIT
10$1,537,684$1,207,534.19$11,606,551,855$11,220,668,219.46$11605.01MWIT

LLY vs WIT: Complete Analysis 2026

LLYHealthcare

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Full LLY Calculator →

WITStock

Wipro Limited operates as information technology (IT), consulting, and business process services company worldwide. It operates through three segments: IT Services, IT Products, and India State Run Enterprise Services (ISRE). The IT Services segment offers IT and IT-enabled services, including digital strategy advisory, customer-centric design, technology and IT consulting, custom application design, development, re-engineering and maintenance, systems integration, package implementation, cloud and infrastructure, business process, cloud, mobility and analytics, research and development, and hardware and software design services to enterprises. It serves customers in various industry sectors, such as healthcare and medical devices, consumer goods and life sciences, retail, transportation and services, communications, media and information services, technology products and platforms, banking, financial services and insurance, manufacturing, hi-tech, energy, and utilities. The IT Products segment provides a range of third-party IT products comprising enterprise platforms, networking solutions, software and data storage products, contact center infrastructure, enterprise security, IT optimization technologies, video solutions, and end-user computing solutions. It serves enterprises in various industries primarily in the India market, which comprise the government, defense, IT and IT-enabled services, telecommunications, manufacturing, utilities, education, and financial services sectors. The ISRE segment offers IT services to entities and departments owned or controlled by the Government of India and/or various Indian State Governments. The company was incorporated in 1945 and is based in Bengaluru, India.

Full WIT Calculator →
📬

Get this LLY vs WIT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LLY vs SCHDLLY vs JEPILLY vs OLLY vs KOLLY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.